Wellhead Biological Technology

Wellhead Biological Technology is a Taiwan-based biotechnology company specializing in the research, development, and manufacture of rare ginsenosides and other natural compounds using patented enzymatic biotransformation technology. The company's lead candidate, Ginsenoside M1, is being investigated for various indications, including oncology (oral cancer), nephrology (lupus nephritis, renal fibrosis), and metabolic diseases (diabetes, gout), with some programs reaching Phase 2 clinical trials. Wellhead also develops Ginsenoside Compound K for neurodegenerative diseases like Huntington's and provides manufacturing services for ginsenoside-based supplements. The company collaborates extensively with academic institutions such as Chang Gung University to elucidate the mechanisms of its bioactive compounds and translate them into therapeutic applications.